To the central content area :::
ECO-Fin
:::
:::Listed Companies > Listed Companies Info. > Main Board Companies > Listed Company Profile

General Stock Board Listed Company Profile

4157 TAIGEN
中文
Company Profile
Chairman CEO Spokesperson Tel Address Date of Listing (Regular)
HUANG, KUO-LUNG HUANG, KUO-LUNG HUANG, KUO-LUNG 0281777020 Box 309, Ugland HouseGrand Cayman, KY1-1104, Cayman Islands 2014/01/17
Agent for litigious
and non-litigious matters
Tel of
Agent for litigious
and non-litigious matters
Address of
Agent for litigious
and non-litigious matters
HUANG, KUO-LUNG 0281777020 7F., NO. 138, XINMING RD., NEIHU DIST., TAIPEI CITY 11470, TAIWAN (R.O.C.)
Industry Main Business
Biotechnology and Medical Care Founded in 2001, TaiGen Biotechnology (TaiGen Taiwan) is a leading research- based and product-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, China. In 2008, TaiGen Taiwan completed a share swap with TaiGen Biopharmaceuticals Holdings Limited (TaiGen Cayman), and has become a fully owned subsidiary of TaiGen Cayman. TaiGen's current pipeline includes therapeutics for infectious diseases, diabetic complications and cancer for the worldwide market. Nemonoxacin is a novel broad-spectrum non-fluorinated quinolone antibiotic under development for respiratory infections. In addition to nemonoxacin, TaiGen has two NCEs in clinical development under IND with US FDA: TG-0054, a chemokine receptor antagonist for stem cell transplantation and chemosensitization and TG-2349, a HCV protease inhibitor for treatment of chronic hepatitis infectio. Both TG- 0054 and TG-2349 are currently in clinical trials in patients in the US.
 
Market Information ( 2024/06/17 )
Shr. Vol. Highest Lowest Closed Change Transaction TurnOver(%) long
margin
balance
(1,000shr.)
Short
margin
balance
(1,000shr.)
2082.407 15.35  15.05  15.35  0.30  786 .00 8,611 0
Trading method Fun
purchase
price or
securities
pneeded
on T day
Announcement of Irregularity
(2024/06/17)
TPEx measures
adopted
(2024/06/17)
With warrants Can be shorted or margined? Detail
Normal N N N Y Y Today History
 
Financial Reports
Cash Flows Items
Amount
(NT$ thousand)
Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Balance
Sheets
Current assets
Non-current assets
Total assets
Current liabilities
Non-current liabilities
Total liabilities
Share capital
Capital surplus
Retained earnings
Other equity interest
Treasury shares
Total equity attributable to owners of parent
Non-controlling interests
Total equity
Book Value per share(NT$)
Comprehensive Income Operating revenue
Operating costs
Gross profit from operations
Operating expenses
Net other income (expenses)
Net operating income
Non-operating income and expenses
Profit before tax
Tax expense
Profit from continuing operations
Profit from discontinued operations
Profit
Other comprehensive income
Comprehensive income
Basic earnings per share
 Auditor's report on latest financial statements: auditor's report:
 More detail:MOPS
 Foreign issuers’ information is disclosed in consolidated statements.